Diffuse Alveolar Hemorrhage: A rare fatal complication of systemic Lupus Erythematosus (A report of two cases)
https://doi.org/10.47895/amp.v56i2.4246
- Author:
Kenzle Denise G. Monsanto
1
;
Geraldine T. Zamora
1
Author Information
1. Philippine General Hospital, University of the Philippines Manila
- Publication Type:Other Types
- Keywords:
Diffuse alveolar hemorrhage
- MeSH:
Lupus Erythematosus, Systemic;
Cyclophosphamide;
Nephritis;
Methylprednisolone
- From:
Acta Medica Philippina
2022;56(2):72-76
- CountryPhilippines
- Language:English
-
Abstract:
We report two Filipino women with systemic lupus erythematosus (SLE) who developed diffuse alveolar hemorrhage (DAH), a rare, life-threatening complication associated with a high mortality rate. DAH should be suspected in patients with SLE presenting with new pulmonary infiltrates, a decline in hemoglobin, hemoptysis, dyspnea, and persistent desaturation. The first patient is 23 years old and was diagnosed with SLE 8 years ago; initially presenting with malar rash, oral ulcers, nephritis, and positive antinuclear antibodies (ANA). She had a poorly controlled disease and was admitted for facial and bipedal edema due to lupus nephritis. She was given 1 gram of methylprednisolone intravenously (IV) for three consecutive days. She then became tachypneic producing bloody secretions, with desaturation and sudden decline in hemoglobin. She was given cyclophosphamide 1 gram IV and referred for plasmapheresis but eventually succumbed. The second patient is 56 years old with generalized body weakness. Laboratory workup showed nephritis, anemia, ANA, low C3, and high anti-dsDNA titers. Pulse methylprednisolone 1000 mg was initiated. However, there was new-onset hemoptysis and desaturation and the patient was intubated. Bronchoscopy revealed diffuse bleeding on the right middle lobe and she eventually expired. Both patients with active SLE nephritis presented in this study died within days of DAH diagnosis. Hence, aside from early recognition to improve outcomes we should anticipate its possible occurrence in patients with high disease activity.
- Full text:4246-Article Text-56038-1-10-20220218.pdf
